Opinion

Video

Understanding CML: Your Journey from Diagnosis to Treatment

Author(s):

Jorge E. Cortes, MD,Joannie Clements

A panel of experts on introduce a discussion on chronic myeloid leukemia (CML) with an overview of the disease, focusing on its subtypes and characteristics.

This program was made possible with support from Novartis Pharmaceuticals.

Video content above is prompted by the following questions:

  • Please provide some background on CML. What are the different subtypes of CML and how do they differ in terms of presentation and management?
  • Can you explain the typical prognosis and disease course for someone diagnosed with CML? How do you educate newly diagnosed patients on what to expect?
Related Videos
Image of a man wearing a suit with a red bowtie.
Related Content
Image of a heart monitor.
October 22nd 2024

Identifying Cardiovascular Disease Risk in Cancer Survivors

Spencer Feldman
The risk of cardiovascular disease is elevated in cancer survivors, regardless of treatment, and is influenced by cancer type and treatment-related factors.
Image of red blood cells.
October 3rd 2024

Education on MPN Symptoms, Treatments Leads to Greater Involvement in Care

Darlene Dobkowski, MA
An expert explained the importance of education and involvement in care for patients with myeloproliferative neoplasms.
Image of red blood cells generated by Adobe Firefly.
September 24th 2024

Reblozyl May Be ‘The Standard of Care’ Now in Lower-Risk MDS, Anemia

Alex Biese
An expert discussed the findings of the COMMANDS trial evaluating Reblozyl’s role in red blood cell transfusion independence for patients with MDS.
Illustration of a woman with short blonde hair.
September 20th 2024

In a World of Rushing, Cancer Taught Me to Slow Down

Jane Biehl Ph.D.
With my myelodysplastic syndrome and age, I find it hard to keep up; however, cancer and fatigue have taught me to live at my own pace.
Illustration of tumor cells among red blood cells.
September 18th 2024

Patients With Lower-Risk Myelofibrosis May Respond to Jakafi

Darlene Dobkowski, MA
Although Jakafi has been approved for patients with higher-risk myelofibrosis, those with lower-risk disease may also benefit from this treatment.
Picture of Dr. Guillermo Garcia-Manero
September 18th 2024

Why Transfusion Independence Matters for Patients With MDS

Alex Biese
An expert explained the burden that red blood cell transfusions can place on patients with MDS.